Ciprian Tomuleasa
Overview
Explore the profile of Ciprian Tomuleasa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
196
Citations
1672
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bancos A, Iancu S, Moisoiu V, Ghiaur A, Tigu A, Buran C, et al.
J Cell Mol Med
. 2025 Mar;
29(5):e70244.
PMID: 40042091
Acute promyelocytic leukaemia (APL) is a type of acute myeloid leukaemia characterised by the reciprocal translocation t(15;17), which offers a unique possibility for measurable residual disease (MRD) monitoring by PCR...
2.
Mesaros O, Jimbu L, Rus I, Parvu A, Tomuleasa C, Dima D, et al.
Med Pharm Rep
. 2025 Feb;
98(1):36-45.
PMID: 39949913
Introduction: The advent of Bruton's tyrosine kinase (BTK) inhibitors brought about a paradigm shift in the management of chronic lymphocytic leukemia (CLL), by offering a well-tolerated chemotherapy-free approach. Here, we...
3.
Timis T, Buruiana S, Dima D, Nistor M, Muresan X, Cenariu D, et al.
Biomedicines
. 2025 Jan;
13(1).
PMID: 39857682
The incidence rate of cutaneous melanoma is on the rise worldwide, due to increased exposure to UV radiation, aging populations, and exposure to teratogen agents. However, diagnosis is more precise,...
4.
Gupta V, Tomuleasa C, Barranco Lampon G, Barranco G, Hou H, Helbig G, et al.
Blood Adv
. 2024 Dec;
9(5):1105-1116.
PMID: 39729499
Myelofibrosis (MF), a myeloproliferative neoplasm, was most commonly treated with hydroxyurea (HU) before approval of ruxolitinib (RUX), now the standard of care. Factors that influence real-world MF treatment patterns are...
5.
Kegyes D, Moisoiu V, Constantinescu C, Tanase A, Ghiaur G, Einsele H, et al.
Blood Rev
. 2024 Dec;
69():101254.
PMID: 39674687
Chemo- and immune therapies administered to treat haematologic malignancies frequently cause neurologic injury. The adverse events range from mild cognitive impairment and headaches to severe conditions such as seizures, stroke...
6.
Tigu A, Munteanu R, Moldovan C, Rares D, Kegyes D, Tomai R, et al.
Cell Death Discov
. 2024 Nov;
10(1):471.
PMID: 39551787
Receptor tyrosine kinases (RTKs) are key cell surface receptors involved in cell communication and signal transduction, with great importance in cell growth, differentiation, survival, and metabolism. Dysregulation of RTKs, such...
7.
Jitaru C, Symeonidis A, Badelita S, Katodritou E, Colita A, Mpanti A, et al.
J Hematol
. 2024 Nov;
13(5):207-215.
PMID: 39493599
Background: Castleman disease (CD) is a very rare, non-malignant lymphoproliferative disorder that can be classified as unicentric or multicentric (MCD). MCD is associated with systemic symptoms, including organ dysfunction due...
8.
Jitaru C, Peters M, Aggarwal L, Bancos A, Tigu A, Cenariu D, et al.
J Cell Mol Med
. 2024 Oct;
28(20):e18592.
PMID: 39435884
No abstract available.
9.
Ursu C, Serban M, Patrascu J, Coriu D, Jr J, Ionita I, et al.
Life (Basel)
. 2024 Sep;
14(9).
PMID: 39337955
Despite the controversies regarding the appropriateness and justification of simultaneous bi- and multi-concomitant surgical procedures, this operative technique is increasingly undertaken for economic reasons. This paper discusses three cases of...
10.
Tomai R, Iluta S, Tigu A, Nistor M, Bancos A, Cenariu D, et al.
Diagnostics (Basel)
. 2024 Sep;
14(18).
PMID: 39335764
: Spontaneous remission of cancer is a rare and poorly understood phenomenon characterized by complete or partial remission of a malignancy in the absence of or with inadequate treatment. The...